Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3974 - Tyrosine kinase inhibitors alone as a first-line treatment for patients with non-small-cell lung cancer harboring mutant epidermal growth factor receptor


08 Oct 2016


Poster Display


Toshihiko Iuchi


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


T. Iuchi1, M. Shingyoji2, M. Itakura3, Y. Hasegawa1, Y. Yoshida2, S. Ikegami1, T. Setoguchi1, H. Ashinuma2

Author affiliations

  • 1 Neurological Surgery, Chiba Cancer Center Hospital, 260-8717 - Chiba/JP
  • 2 Respirology, Chiba Cancer Center Hospital, 260-8717 - Chiba/JP
  • 3 Respirology, Chiba Cancer Center Hospital, Chiba/JP


Abstract 3974


Brain metastases (BMs) are a frequent complication of non-small-cell lung cancer (NSCLC). Whole brain radiation therapy (WBRT) is a standard treatment for BMs, but favorable response of BMs with mutant epidermal growth factor receptor (EGFR) against tyrosine kinase inhibitors (TKIs) have also been reported. The aim of this study is to clarify the effect of TKIs alone without radiation therapy for BMs from EGFR-mutant NSCLC.


BMs from NSCLC with EGFR-mutation were enrolled. Gefitinib was administrated first, and erlotinib or afatinib was used at tumor progression. Erlotinib (or afatinib) was also selected for patients whose BMs had developed after gefitinib (or erlotinib). The primary endpoint was overall survival after BM (OS), and the secondary endpoints were maximum response to TKIs, time to progression of intracranial lesions, and time to salvage radiation therapy (RT).


In this study, 108 patients with BMs were enrolled. The types of mutations were as follows: exon 19 deletion in 62, exon 20 L858R in 39, and other types of mutations in 7 cases. During the follow-up period, 70 deaths were observed but only 17 of these deaths were owing to the progression of intracranial lesions. The medium OS was 20.9 months. The response rates of first-line and second-line TKIs were 76.9% and 70.6%, respectively. The medium time to progression of intracranial lesions was 14.5 months, and medium time to salvage RT was 19.0 months. Among the patients, gefitinib was administrated in 83 (first-line) and erlotinib in 59 (fist-line:22, second-line, 37) cases. The response rates of gefitnib and erlotinib were 76.8% and 78.6%, and the time to progression of intracranial lesions after gefitinib and erlotinib were 13.9 and 20.3 months, respectively. We could not find any significantly different response of BMs to TKIs owing to the types of mutations.


TKIs showed favorable control of BMs harboring EGFR-mutation without RT. At progression, other types of TKIs still showed excellent effect. TKIs first treatment could postpone RT, and feasible for BMs from EGFR-mutant NSCLC.

Clinical trial identification

Legal entity responsible for the study

Chiba Cancer Center




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings